+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Herpes Simplex Virus Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997585
  • Report
  • March 2020
  • Region: Global
  • 117 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Apotex Inc.
  • Avet Pharmaceuticals Inc.
  • Carlsbad Tech
  • Epi Health LLC
  • Fresenius Kabi
  • GlaxoSmithKline LLC
  • MORE
The Herpes Simplex Virus Treatment Market is expected to register a CAGR of 5.9% during the forecast period owing to growing prevalence of simplex herpes virus. Herpes Simplex Virus is of two types, HSV-1 and HSV-2. According to the World Health Organization, in 2017, around 3.7 billion people globally, were diagnosed with HSV-1 aged under fifty. Moreover, HSV-2 occurred in 417 million people worldwide aged between 11 and 49. Hence, such higher prevalence of herpes simplex virus is expected to boost the market growth.

Key Market Trends

Acyclovir Segment is Expected to Hold a Significant Market Share in the Herpes Simplex Virus Treatment Market
  • Acyclovir is a anti-viral therapy considered as the majorly used treatment in case of herpes, used against oral herpes and HSV encephalitis. It is purine nucleoside analog that enters into viral DNA to restrict it’s replication process by converting into acyclovir triphosphate. According to the study published in 2019, by Frontiers in Microbiology acyclovir when given in combination with omeprazole increased the anti-viral effects in HSV-1 and HSV-2 infection.
  • Also, growing burden of HSV encephalitis is expected to boost the market in this particular segment. According to National Organizations for Rare Disorders, the incidence of acute encephalitis in the United States is around 2,000 cases per year and it constitutes for atleast 10% of total cases of encephalitis occurring in the United States.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be dominant in genital herpes market owing to growing prevalence of infections of herpes simplex virus. According to American Sexual Health Association, approximately fifty percent of population in the United States suffers from oral herpes which is caused by HSV-1. Furthermore, around one in eight people is likely to suffer from HSV-2 infection. Moreover, according to the National Institutes of Health, by the age of 50 around 90% of people in the United States are exposed to this virus. Hence, this emerges the need for treatment of herpes and thereby expected to drive the herpes simplex virus treatment market.

Competitive Landscape

Some of the companies which are currently dominating the market are Teva Pharmaceuticals Inc., Apotex Inc., Mylan Pharmaceuticals Inc., Epi Health LLC, Zydus Pharmaceuticals, GlaxoSmithKline LLC, Carlsbad Tech, Avet Pharmaceuticals Inc., Glenmark Pharmaceuticals Inc. and Fresenius Kabi

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apotex Inc.
  • Avet Pharmaceuticals Inc.
  • Carlsbad Tech
  • Epi Health LLC
  • Fresenius Kabi
  • GlaxoSmithKline LLC
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Genital Herpes
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 Product Recalls
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Acyclovir
5.1.2 Valacyclovir
5.1.3 Famciclovir
5.1.4 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injection
5.2.3 Topical
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceuticals Inc.
6.1.2 Apotex Inc.
6.1.3 Mylan Pharmaceuticals Inc.
6.1.4 Epi Health LLC
6.1.5 Zydus Pharmaceuticals
6.1.6 GlaxoSmithKline LLC
6.1.7 Carlsbad Tech
6.1.8 Avet Pharmaceuticals Inc.
6.1.9 Glenmark Pharmaceuticals
6.1.10 Fresenius Kabi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Teva Pharmaceuticals Inc.
  • Apotex Inc.
  • Mylan Pharmaceuticals Inc.
  • Epi Health LLC
  • Zydus Pharmaceuticals
  • GlaxoSmithKline LLC
  • Carlsbad Tech
  • Avet Pharmaceuticals Inc.
  • Glenmark Pharmaceuticals
  • Fresenius Kabi
Note: Product cover images may vary from those shown
Adroll
adroll